Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families

Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield · 2026

Read Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families by Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13423122.txt.

Description

Maria Gnarra Buethe and colleagues offer an advice guide in 2026 on dupilumab safety and lymphoma worry for children with eczema. Reports linking the eczema drug to cutaneous T-cell lymphoma, amplified by media coverage, have fueled parent worry. Infant approval in 2022 means the longest exposures now span only three to four years.

The guide reviews long-term extension data, untangles eczema from early lymphoma, which can look alike, and sets out monitoring and advice steps. Pediatric teams gain a data-driven script for answering families who fear trading eczema relief for lymphoma risk.

Catalog record

CREATORMaria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13423122

Browse the full library · About the Tower of Babel